Corindus appoints Mark J Toland as president and chief executive officer

162

Corindus Vascular Robotics has appointed announced Mark Toland as chief executive officer and member of the Board of Directors. He replaced David Handler, who has announced his resignation.

Toland joins Corindus from Boston Scientific, where he most recently held the position of senior vice president, Corporate Accounts & Global Healthcare Solutions. He brings more than 20 years of operating experience in the cardiovascular medical device industry to Corindus. Toland spent more than 18 years at Boston Scientific where he led large divisional and corporate teams responsible for US commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology.

“Mark is a highly respected industry veteran with proven leadership skills and an exceptional track record of growing organizations within the interventional cardiovascular industry,” says Jeffrey Lightcap, chairman of Corindus’ Board of Directors. “Mark’s deep cath lab insights and strategic vision will be instrumental to leading Corindus as we build upon our strong foundation and work to capture the significant potential of robotics in the cath lab.”

Commenting on his appointment, Mark Toland says, “The global opportunity for precision vascular robotics is tremendous… I am excited to join Corindus and look forward to working with the healthcare community on enhancing patient outcomes while reducing radiation exposure and ergonomic strain to physicians and healthcare providers.”